Literature DB >> 22430276

Patient-reported outcomes after hepatic resection of colorectal cancer metastases.

Jonathan R Rees1, Jane M Blazeby, Peter Fayers, Elizabeth A Friend, Fenella K S Welsh, Timothy G John, Myrddin Rees.   

Abstract

PURPOSE: Hepatic resection of colorectal carcinoma (CRC) liver metastases is increasing, but evidence for the impact of surgery on patient-reported outcomes (PROs) is limited. This study aimed to describe comprehensively the impact of liver surgery for CRC hepatic metastases on PROs. PATIENTS AND METHODS: Consecutive patients selected for hepatic resection completed the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 and Quality of Life Questionnaire-Liver Metastases C21 before and 3, 6, and 12 months after surgery. For functional scales, mean scores with 95% CIs were calculated at each time point, with differences in scores of at least 10 points considered clinically significant. Responses to symptom scales and items were categorized as minimal or severe. Proportions and 95% CIs for each symptom category were calculated.
RESULTS: Hepatic surgery was planned in 241 patients but abandoned in nine because of unresectable disease. There were two postoperative deaths, 58 complications (25.2%), and 32 patients (14.9%) with disease recurrence. Questionnaire compliance was excellent (> 95% at all time points). After surgery, most functional aspects of health decreased, and the proportions of patients with severe symptoms increased; role function deteriorated significantly, and 30% of patients reported severe activity/vigor problems. Functional scales recovered by 6 months and were maintained at 1 year. Postoperative symptoms returned to baseline levels at 12 months, but 32.1% of patients reported severe problems with sexual dysfunction and 11.9% with abdominal pain.
CONCLUSION: These findings provide new evidence regarding outcomes of liver resection for CRC metastases. It is recommended that patients be reassured that surgery has a minimal and short-lived detrimental impact on health.

Entities:  

Mesh:

Year:  2012        PMID: 22430276     DOI: 10.1200/JCO.2011.38.6177

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

1.  Gastrointestinal cancer: The PROs and cons of liver resection in colorectal cancer.

Authors:  M Teresa Villanueva
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

2.  Severe Preoperative Symptoms Delay Readiness to Return to Intended Oncologic Therapy (RIOT) After Liver Resection.

Authors:  Heather A Lillemoe; Rebecca K Marcus; Bradford J Kim; Nisha Narula; Catherine H Davis; Qiuling Shi; Xin Shelley Wang; Thomas A Aloia
Journal:  Ann Surg Oncol       Date:  2019-08-14       Impact factor: 5.344

Review 3.  Assessment of the reporting of quality and outcome measures in hepatic resections: a call for 90-day reporting in all hepatectomy series.

Authors:  Michael E Egger; Joanna M Ohlendorf; Charles R Scoggins; Kelly M McMasters; Robert C G Martin
Journal:  HPB (Oxford)       Date:  2015-07-30       Impact factor: 3.647

4.  Wireless Monitoring Program of Patient-Centered Outcomes and Recovery Before and After Major Abdominal Cancer Surgery.

Authors:  Virginia Sun; Sinziana Dumitra; Nora Ruel; Byrne Lee; Laleh Melstrom; Kurt Melstrom; Yanghee Woo; Stephen Sentovich; Gagandeep Singh; Yuman Fong
Journal:  JAMA Surg       Date:  2017-09-01       Impact factor: 14.766

5.  Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer.

Authors:  J Rees; C N Hurt; S Gollins; S Mukherjee; T Maughan; S J Falk; J Staffurth; R Ray; N Bashir; J I Geh; D Cunningham; R Roy; J Bridgewater; G Griffiths; L S Nixon; J M Blazeby; T Crosby
Journal:  Br J Cancer       Date:  2015-07-23       Impact factor: 7.640

6.  Overexpression of chemokine receptor CXCR2 and ligand CXCL7 in liver metastases from colon cancer is correlated to shorter disease-free and overall survival.

Authors:  Thibault Desurmont; Nicolas Skrypek; Alain Duhamel; Nicolas Jonckheere; Guillaume Millet; Emmanuelle Leteurtre; Pierre Gosset; Belinda Duchene; Nassima Ramdane; Mohamed Hebbar; Isabelle Van Seuningen; François-René Pruvot; Guillemette Huet; Stéphanie Truant
Journal:  Cancer Sci       Date:  2015-03-05       Impact factor: 6.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.